Belgian Construction Stock News

On October 31, 2025, Cmb.Tech NV was removed from the Euronext 150 Index, an important benchmark for European equities. Such index exclusions can lead to substantial portfolio adjustments by institutional investors, as many funds track or benchmark to major indices. We'll explore how Cmb.Tech's index removal could reshape its investment narrative, especially given potential shifts in institutional ownership. We've found 14 US stocks that are forecast to pay a dividend yield of over 6% next...

UCB (ENXTBR:UCB) received FDA approval for KYGEVVI, marking a major step in rare disease treatment. KYGEVVI is the first approved therapy for TK2d, a life-threatening mitochondrial disorder with very limited options. See our latest analysis for UCB. Following the FDA approval for KYGEVVI, UCB's momentum has been building. The share price has climbed nearly 20% year-to-date. After some short-term volatility, the stock's 1-year total shareholder return stands at an impressive 26%. Those who...

One way to deal with stock volatility is to ensure you have a properly diverse portfolio. Of course, the aim of the...

Montea Comm. VA (ENXTBR:MONT) just announced its earnings for the first nine months of 2025, showing higher sales compared to last year, but both net income and earnings per share declined. See our latest analysis for Montea Comm. VA. Despite Montea Comm. VA’s mixed nine-month results, investor sentiment has shown resilience, with the share price rising 12.2% year-to-date and the one-year total shareholder return reaching a solid 14.3%. While long-term three-year returns remain positive, the...

Syensqo reported third quarter 2025 earnings, revealing sales of €1.56 billion and net income of €39 million, compared to a third quarter net loss in 2024, despite a year-on-year decline in revenue for both the quarter and nine months ending September 30. The company’s rebound to profitability in the third quarter, following a loss a year earlier, underscores a shift in its performance trend even amid lower sales. We’ll assess how Syensqo’s return to quarterly profit, despite weaker sales,...

UCB announced that KYGEVVI, a combination therapy for thymidine kinase 2 deficiency (TK2d), has received approval from the U.S. FDA, making it the first and only approved treatment for this ultra-rare, life-threatening mitochondrial disorder in both adults and pediatric patients with symptom onset before age 12. This approval provides UCB with entry into a new therapeutic area with high unmet need, and comes with a Rare Pediatric Disease Priority Review Voucher from the FDA, highlighting...

Lotus Bakeries was recently added to the Euronext 150 Index, highlighting its growing profile among Europe’s largest listed companies. This milestone can influence share demand as index-tracking funds and institutional investors may adjust holdings to include the company. We’ll now explore how inclusion in a major index could impact Lotus Bakeries’ investment narrative and future institutional interest. AI is about to change healthcare. These 32 stocks are working on everything from early...

The Realco SA ( EBR:REAL ) share price has done very well over the last month, posting an excellent gain of 32%. The...

This week we saw the Banqup Group SA ( EBR:BANQ ) share price climb by 11%. But that doesn't change the fact that the...

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...

Montea Comm. VA recently reported earnings for the nine months ended September 30, 2025, with sales rising to €110.65 million from €89.71 million a year earlier and net income reaching €114.92 million, slightly lower than the prior year. Despite stronger sales, the company posted lower net income and basic earnings per share, highlighting pressures on profitability despite revenue growth. We'll explore how Montea Comm. VA's increased sales but contracting profit margins could shape the...

Anheuser-Busch InBev announced a US$6 billion share repurchase program and released its third quarter 2025 earnings, reporting sales of US$15.13 billion and net income of US$1.05 billion for the quarter ended September 30, 2025. The board also approved an interim dividend, renewed a key services framework with its Asia-Pacific subsidiary, and disclosed the upcoming departure of its longstanding Chief People Officer, marking a period of significant corporate actions. We'll explore how the...

NV Bekaert (ENXTBR:BEKB) has just been added to the Euronext 150 Index, catching the attention of the market. Inclusion in a major index often brings new opportunities from institutional and passive investors alike. See our latest analysis for NV Bekaert. Bekaert's inclusion in the Euronext 150 seems to have energized market sentiment, coinciding with a 2.12% one-day bump in the share price and capping off a 15.74% total shareholder return for the past year. The stock's longer-term track...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Key Insights Significant control over Sofina Société Anonyme by private companies implies that the general public has...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Proximus recently reported mixed third-quarter results, highlighting steady domestic growth but sharp declines in its international division, where revenue dropped by 19% and EBITDA by 25% year-on-year due to competitive pressures and integration challenges. The company confirmed an interim dividend of €0.30 per share, reaffirmed progress toward a €600 million asset sale target by 2027, and indicated its global segment will likely face continued headwinds into 2026. We'll explore how the...

Key Insights Given the large stake in the stock by institutions, ageas' stock price might be vulnerable to their...

Umicore (ENXTBR:UMI) shares have experienced mixed momentum in recent weeks, drawing attention from investors curious about what might drive the next move. The company's stock has delivered strong gains over the past year, yet it remains below the highs from previous years. See our latest analysis for Umicore. Umicore’s share price has seen a remarkable revival in 2024, climbing 61.4% year-to-date and taking total shareholder return over the past twelve months to 57.1%. However, the three-...

Solvay (ENXTBR:SOLB) has drawn attention after confirming its 2025 guidance even as tariff issues affect its Brazilian business. The company also approved a stable interim dividend and reported stronger net profit, sparking investor interest. See our latest analysis for Solvay. Momentum around Solvay has been choppy this year, with the company’s confirmation of 2025 guidance and recent profit beat offering reassurance after a challenging stretch. While the share price is down nearly 14%...

Proximus (ENXTBR:PROX) is drawing increased attention as its Q3 2025 earnings call approaches on November 7. This event typically offers investors important updates regarding the company’s recent performance and future direction. See our latest analysis for Proximus. Proximus has experienced a volatile period recently, with a 7.24% decline in share price over the past week and an 8.05% decrease over the last month. Despite this recent decline, the share price is still up 35.72% year-to-date,...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

argenx (ENXTBR:ARGX) shares have climbed around 6% over the past month, catching the interest of investors looking for signs of sustainable momentum. The stock’s double-digit annual revenue and earnings growth adds to the intrigue as the company pushes forward in the biotech space. See our latest analysis for argenx. Momentum has been building for argenx, with a 28.5% share price return over the past three months and a stellar one-year total shareholder return of 31.7%. Investors seem to be...

Solvay SA recently reported its third quarter and nine-month 2025 results, revealing sales of €1,011 million and nine-month sales of €3.16 billion, both lower than the prior year, but with third quarter net income rising to €34 million from €19 million a year ago. An interesting aspect is that despite lower sales and revenue figures, Solvay managed to increase earnings per share and net income in the third quarter compared to the same period last year, signaling potential cost controls or...